- Dr. Torsten Passie is a leading international expert on hallucinogenic drugs and author of The Science of Microdosing Psychedelics
- He joins an elite team of leaders in pharmacology and neuropsychiatry on Diamond’s scientific advisory board
TORONTO, Oct. 5, 2021 /CNW/ – Diamond Therapeutics Inc. (“Diamond”), a drug development company focused on low-dose psychedelic therapies for use in the treatment of mental health, is pleased to announce the appointment of Dr. Torsten Passie to its scientific advisory board.
Dr. Passie is a professor of psychiatry and psychotherapy at Hannover Medical School in Hannover, Germany and an internationally recognized authority on the pharmacology and therapeutic use of psychedelics.
Dr. Passie is also a visiting scientist at the Senckenberg Institute of History and Ethics in Medicine at Goethe University Frankfurt. He is the former director of the Laboratory for Neurocognition and Consciousness at Hannover Medical School and has done extensive research on the therapeutic potential of hallucinogenic drugs. Dr. Passie was a visiting professor at Harvard Medical School from 2012 to 2015.
Dr. Passie has published numerous articles in prestigious scientific journals and is the author of The Science of Microdosing Psychedelics (2019). This book set the standard for understanding the microdosing of psychedelics such as psilocybin. Other books by Dr. Passie include The Pharmacology of LSD (2010), Healing with Entactogens (2012) and The History of MDMA (2021).
“Diamond was the first company to generate valid data demonstrating that there is therapeutic potential from repeated low doses of psilocybin,” says Dr. Passie.
“It’s a great honour to be working with Diamond to further investigate the potential of low-dose psychedelics to impact mental health treatments.”
“I’m thrilled to add Dr. Passie to Diamond’s already elite advisory board,” says chair Dr. Edward Sellers. “Dr. Passie’s deep understanding of psychedelics and psychiatry will help advance Diamond’s plans to develop effective mental health treatments that are accessible to patients when their efficacy and safety has been proven.”
Diamond Therapeutics’ scientific advisory board comprises an esteemed group of experts in neuroscience, pharmacology, psychiatry, drug discovery, and pre-clinical and clinical neuropsychiatric drug development.
- Dr. Edward Sellers, professor emeritus of Pharmacology, Toxicology, Medicine and Psychiatry at the University of Toronto
- Dr. Paul Glue, Hazel Buckland Chair and professor of psychological medicine at the Dunedin School of Medicine at the University of Otago, New Zealand
- Dr. Thomas Kosten, J.H. Waggoner Chair and professor of psychiatry, pharmacology, immunology, pathology and neuroscience, emeritus director of the Dan L. Duncan Institute for Clinical and Translational Research at Baylor College of Medicine
- Dr. Joseph Moskal, distinguished research professor and director of the Falk Center for Molecular Therapeutics at Northwestern University
- Dr. Torsten Passie, visiting scientist at the Senckenberg Institute for History and Ethics in Medicine, Goethe University Frankfurt and professor of psychiatry and psychotherapy at Hannover Medical School, Germany
- Dr. William J. Tyler, co-founder of IST LLC and Thync and associate professor in the School of Biological and Health Systems Engineering at Arizona State University
About Diamond Therapeutics
Diamond Therapeutics is a psychedelic drug development company based in Toronto.
Our mission is to develop new and better therapies for mental health conditions by
unlocking the promise of psychedelic compounds. Diamond is focused on sub-
perceptual, non-hallucinogenic treatments that hold potential for use across a broad
patient cohort —maximizing the positive impact better drugs can have on the global
mental health crisis. To learn more about Diamond, visit www.diamondthera.com.
Cautionary Statements Regarding Forward-Looking Information
This news release includes certain “forward-looking information” under applicable Canadian securities legislation. Forward-looking information includes statements other than statements of historical fact that can be identified by phrases such as “expects”, “anticipates”, “intends”, “aims”, “plans” and “believes”, and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements in this news release include, but are not limited to, the potential effects of low dose psilocybin and other psychedelic treatments, the potential use in treating mental health conditions and the timing and completion of Diamond’s clinical programs and trials. Forward-looking information is necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; delay or failure to receive applicable regulatory approvals; that factors may occur which impede Diamond’s future business plans; the results of continued development, marketing and sales; and other factors beyond the control of Diamond. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Diamond disclaims any intention or obligation to update or revise any forward-looking information in this news release, whether as a result of new information, future events or otherwise, except as required by law.
SOURCE Diamond Therapeutics Inc.
For further information: Rebecca Brown, firstname.lastname@example.org